Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Ryan

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideD E Rathkopf, M R Smith, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideD E Rathkopf, M R Smith, C J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancerC J Pezaro, A Omlin, K Mastris, et al.
Pageof 10